In the United States over 24 million people are affected with diabetes at a cost of over $170 Billion annually. Each year about 1.6 million new diabetes cases are diagnosed in adults. In approximately 20% of diabetic patients, the disease reaches a stage where serious complications develop and begin to progress, including the loss of feeling in the hands and feet, persistent wounds, many forms of pain, poor sleep, low energy, eyesight degradation, and the loss of kidney and heart function. Patients who have developed these complications do not see their conditions relieved by beginning or continuing tight control of their blood sugar with drugs and subcutaneous insulin shots. In these patients, the disease will continue to progress which is why diabetes is the leading cause of blindness, kidney failure, heart disease and amputations. The prognosis for people with advanced diabetic complications has been quite dim, until now.
Microburst Insulin Infusion (MII) represents a major shift in the approach to treating advanced diabetes complications. MII is an intravenous treatment, administered in a clinical setting, that utilizes a precise high-pressure pulsation algorithm to intelligently perfuse insulin into a diabetic patient- effectively mimicking the effect that a normal pancreas has on the liver. The treatment stimulates the liver to produce critical metabolic enzymes otherwise absent or dramatically reduced in both type 1 and type 2 diabetics. Rather than working to control blood sugar, MII treats an advanced diabetic’s metabolic disorder by restoring their ability to properly convert carbohydrates into cellular energy. Because the onset and progression of advanced diabetes complications are due primarily to a patient’s inability to use carbohydrates for cellular energy, MII re-opens a critical pathway for a healthier metabolism—tissues heal, and the serious complications from advanced diabetes are halted or reversed.
The nerve cells are highly dependent on glucose metabolism. Without glucose metabolism, nerve cells starve and eventually will die. When patients with neuropathy begin MII treatments, the nerves throughout the body are immediately fed and begin to respond in a surprising but normal way.
A combination of being able to feel your feet, experiencing increased blood flow and improved health of the tissues will reduce the chance of blisters developing again and heal those that are already in place. This could mean preventing amputations.
Patients with sexual dysfunction (both male and female) can expect to regain that function, as feeling and increased blood flow returns to all of the extremities. ED can be reversed if the patient was able to achieve an erection within the last 5 to 10 years.
Hypoglycemic awareness is restored and reduced by 98%.
Dramatic improvement in hypertension in just 90 days. Amounts of medications necessary to maintain acceptable blood pressure levels will be reduced or eliminated.
Patients’ wounds heal, even if these wounds have not closed for many years. Diabetes is the number-one cause of non-traumatic amputations worldwide. These amputations should be avoided for any patients on MII treatments as most all of the wounds are expected to heal. With increased blood flow, future wounds can be avoided as the skin gets healthier. Feeling returns to the extremities, allowing an awareness if a blister is developing.
Chronic Fatigue and Muscle Fatigue
Effectively treated by the therapy, patients will see dramatic energy level improvement, particularly where energy levels have become a problem.
Patients with chronic kidney disease (CKD) experience a loss of creatinine clearance (CrCl) of 8-10 “points” per year (units are mL/min) even when they are tightly controlling their blood sugar. With MII, this filtration related number has been proven to improve dramatically. This means that patients with 1/3 of their kidney function (CrCl
> 30 – 40) should never progress to dialysis, and those with higher function will actually increase their filtration levels. Also, protein in the urine will be reduced. Patients with CrCl > 50 – 60 have seen their kidneys actually improve their functioning level.
Individuals with diabetes in CKD Stage 3 and 4 should never advance to Stage 5 (End Stage Renal Disease) and dialysis. Those in Stage 3A will most likely begin to improve their kidney function.
The cells in the eyes are particularly sensitive to glucose metabolism. Most patients who were experiencing vision problems due to their diabetes report improved vision after just a few MII sessions. This includes color recognition and brightness.
Patients with diabetic retinopathy can expect to avoid further laser treatment. Depending on the severity of their current condition, they should expect improving eye health and significant vision improvement.
When GI problems are caused by diabetes, patients have seen relief as a result of MII treatments. Gastroparesis is a form of neuropathy, so patients have seen rapid relief from this complication of the disease.
The heart muscle responds very well to the MII treatment and increased carbohydrate metabolism. The heart especially enjoys carbohydrate metabolism because there is no need for the extra oxygen required for lipid and free fatty acid metabolism. That is why diabetes heart disease (cardiomyopathy) is a major problem which does not respond well to tight glucose control. (In fact, tight glucose control worsens diabetic heart disease and has been reported to cause more frequent heart attacks). MII patients with low ejection fractions can expect to improve dramatically and return to significantly higher ejection fractions and higher energy levels. This reduces the chances of congestive heart failure which is the cause of many diabetic deaths.